Phase 2 Myeloma Trial, Recruiting NCT06793449 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Myeloma
Back to Myeloma

Phase 2 Myeloma Trial, Recruiting

NCT06793449
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been fully informed about the trial and have signed a consent form agreeing to take part voluntarily.
  • People aged between 18 and 70 years old (inclusive).
  • People whose multiple myeloma can be measured through at least one of the following: a certain level of abnormal protein (M-protein) detected in the blood or urine, or abnormal levels of specific proteins called free light chains detected in the blood (confirm with trial site for exact values).
  • People whose myeloma cells have been confirmed to carry a specific marker called BCMA, as shown by laboratory testing of bone marrow samples.
  • People assessed by the treating doctor as being suitable candidates for a stem cell transplant.

Who may not be able to join:

  • People diagnosed with primary plasma cell leukemia (a specific and aggressive form of blood cancer).
  • People who also have a condition called amyloidosis (a disease where abnormal proteins build up in organs and tissues).
  • People whose myeloma has spread to the central nervous system (the brain and spinal cord).
  • People who have previously received any treatment that targeted the BCMA protein, or who have previously had CAR-T cell therapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-022-23909171

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
5 February 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Persistent MRD-negative rate; Progression free survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov